At the time of writing, Jazz Pharmaceuticals plc [JAZZ] stock is trading at $136.69, up 0.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The JAZZ shares have gain 2.04% over the last week, with a monthly amount glided 11.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on February 13, 2025, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $170 from $130. Previously, Morgan Stanley upgraded its rating to Overweight on December 12, 2024, and elevated its price target to $175. On June 05, 2024, Goldman initiated with a Buy rating and assigned a price target of $169 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $160 on January 03, 2024. UBS downgraded its rating to a Neutral and reduced its price target to $135 on November 27, 2023.
For the past year, the stock price of Jazz Pharmaceuticals plc fluctuated between $99.06 and $138.27. Currently, Wall Street analysts expect the stock to reach $182.75 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $136.69 at the most recent close of the market. An investor can expect a potential return of 33.7% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
According to Jazz Pharmaceuticals plc [NASDAQ:JAZZ], the company’s sales were 3.99B for trailing twelve months, which represents an 8.52% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 134.52 points at the first support level, and at 132.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 138.35, and for the 2nd resistance point, it is at 140.00.
Ratios To Look Out For
It is important to note that Jazz Pharmaceuticals plc [NASDAQ:JAZZ] has a current ratio of 4.26. On the other hand, the Quick Ratio is 3.74, and the Cash Ratio is 2.15. Considering the valuation of this stock, the price to sales ratio is 2.07, the price to book ratio is 1.98 and price to earnings (TTM) ratio is 19.69.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Feb 03 ’25 when 1500.0 shares were sold. Officer, COZADD BRUCE C completed a deal on Feb 03 ’25 to buy 1500.0 shares. Meanwhile, Chairman & CEO COZADD BRUCE C sold 1500.0 shares on Jan 02 ’25.
